Trial · NCT03263091
Adverse events1,074
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
61 to 80 of 1,074
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dry eye | Eye disorders | OL Component (Cohort 1): Roxadustat 1.5 mg/kg | 0 | 8 | |
| other | Dry eye | Eye disorders | OL Component (Cohort 2): Roxadustat 2.0 mg/kg | 0 | 8 | |
| other | Dry eye | Eye disorders | OL Component (Cohort 3): Roxadustat 2.5 mg/kg | 1 | 8 | |
| other | Dry eye | Eye disorders | OL High-EPO Component: Roxadustat 2.5 mg/kg | 0 | 20 | |
| other | Dry eye | Eye disorders | DB Component: Roxadustat | 1 | 82 | |
| other | Dry eye | Eye disorders | DB Component: Placebo | 0 | 58 | |
| other | Visual impairment | Eye disorders | OL Component (Cohort 1): Roxadustat 1.5 mg/kg | 0 | 8 | |
| other | Visual impairment | Eye disorders | OL Component (Cohort 2): Roxadustat 2.0 mg/kg | 0 | 8 | |
| other | Visual impairment | Eye disorders | OL Component (Cohort 3): Roxadustat 2.5 mg/kg | 0 | 8 | |
| other | Visual impairment | Eye disorders | OL High-EPO Component: Roxadustat 2.5 mg/kg | 1 | 20 | |
| other | Visual impairment | Eye disorders | DB Component: Roxadustat | 0 | 82 | |
| other | Visual impairment | Eye disorders | DB Component: Placebo | 0 | 58 | |
| other | Abdominal discomfort | Gastrointestinal disorders | OL Component (Cohort 1): Roxadustat 1.5 mg/kg | 0 | 8 | |
| other | Abdominal discomfort | Gastrointestinal disorders | OL Component (Cohort 2): Roxadustat 2.0 mg/kg | 0 | 8 | |
| other | Abdominal discomfort | Gastrointestinal disorders | OL Component (Cohort 3): Roxadustat 2.5 mg/kg | 0 | 8 | |
| other | Abdominal discomfort | Gastrointestinal disorders | OL High-EPO Component: Roxadustat 2.5 mg/kg | 1 | 20 | |
| other | Abdominal discomfort | Gastrointestinal disorders | DB Component: Roxadustat | 2 | 82 | |
| other | Abdominal discomfort | Gastrointestinal disorders | DB Component: Placebo | 0 | 58 | |
| other | Abdominal distension | Gastrointestinal disorders | OL Component (Cohort 1): Roxadustat 1.5 mg/kg | 0 | 8 | |
| other | Abdominal distension | Gastrointestinal disorders | OL Component (Cohort 2): Roxadustat 2.0 mg/kg | 1 | 8 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03263091/events?page=4